Alexion Pharmaceuticals ( ALXN) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. This stock is trading up 2.2% at $74 in recent trading after hitting a 52-week high of $74.44 earlier in the day. Today's Range: $72.00-$74.44 52-Week Range: $40.04-$73.05 Volume: 464,000 Three-Month Average Volume: 1.2 million Alexion Pharmaceuticals has a market cap of $13.61 billion and an enterprise value of $12.96 billion. The stock trades at a trailing price-to-earnings of 91.22 and a forward price-to-earnings of 44.83. Its estimated growth rate for this year is 46.1%, and for next year it's pegged at 26.2%. The current short interest as a percentage of the float for Alexion Pharmaceuticals is very low at 1.5%. From a technical standpoint, ALXN recently triggered a breakout trade when the stock took out some past overhead resistance at $70.50 to $72.50. This move today in the stock has pushed shares into all-time high territory, which is bullish for any stock. Market players should continue to look for long biased trades as long as ALXN can continue to trend above $70.50 to $72.50. Alexion is one of TheStreet Ratings' top-rated biotechnology stocks. To see more stocks hitting new 52-week highs today, check out the Stocks Hitting New 52-Week Highs portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.